Arrowhead’s REDEMPLO nears EU approval following positive CHMP opinion
Arrowhead Pharmaceuticals is on the verge of its first European commercial launch after regulatory advisors recommended the approval of its siRNA therapy, REDEMPLO, for a rare and potentially life-threatening lipid disorder.









_1386286_640x360_2497553987587-640x360.webp&w=3840&q=75)

